Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Prolonged tioguanine therapy for IBD well tolerated, effective in maintenance setting

15 Jul 2019

Use of tioguanine for at least 12 months appears to be effective in the maintenance treatment of inflammatory bowel disease (IBD), and while adverse events are common, most are clinically tolerable, according to a recent study.

The study population comprised 274 tioguanine-treated IBD patients (median age at tioguanine initiation, 43 years; 63 percent female; 68 percent had Crohn’s disease). Median duration of treatment was 51 months, with median tioguanine dosage being 20 mg/d. There were 1,567 patient-years of follow-up.

Clinical effectiveness (defined as treatment response without [re]initiation of corticosteroids, concurrent biological therapy or surgical intervention) at 6 months was documented in 66 percent of patients, while sustained clinical effectiveness for 12 months was reported in 51 percent. Treatment was tolerable in most patients (79 percent).

Adverse events occurred in 41 percent of patients, including 5 percent who developed events graded as severe. Three patients had infection requiring hospitalization, while eight had skin cancer (two melanomas). Asymptomatic nodular regenerative hyperplasia of the liver occurred in two out of 52 patients with liver biopsies, and portal hypertension was recorded in three, including one case potentially associated with tioguanine.

Clinical effectiveness correlated with 6‐thioguanine nucleotide threshold concentrations >682 pmol/8×10RBC (p<0.05).

In light of the findings, researchers stressed that the therapeutic benefit of tioguanine needs to be balanced with associated toxicity when considering a role for this thiopurine‐derivative in IBD treatment. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Aug 2019

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.